Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Requests Withdrawal Of Endo's Opana ER

Jun 09 2017

• By Sue Sutter

Related Content

Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

Apr 07 2017

FDA Moves On Endo’s Opana ER Unlikely To Sweep Up Other Opioids

Mar 16 2017

Opana ER Should Come Off The US Market, FDA Tells Endo

Jun 09 2017

Related Companies

Endo, Inc.

Genentech, Inc.

Additional Topics

Companies Drug Safety FDA Regulation BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window